BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE | A211699 | MYLAN PHARMACEUTICALS INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
AstraZeneca AB et al v. Mylan Pharmaceuticals Inc. et al 5 patentsANDA 211699budesonide/formoterol fumarate dihydrate | WVND | 2022-04-26 | Terminated 2023-03-08 | — |
AstraZeneca AB et al v. Mylan Pharmaceuticals Inc. et al 4 patentsANDA 211699budesonide/formoterol fumarate dihydrate | WVND | 2018-10-12 | Terminated 2023-03-08 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$20.53
per gm
Lowest NADAC/Unit
$17.71
per gm
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00378750332BREYNA 160-4.5 MCG INHALER | $20.53 | GM | Generic | — | 2026-10-21 |
| 00378750232BREYNA 80-4.5 MCG INHALER | $17.71 | GM | Generic | — | 2026-10-21 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.